Engineered immune cells take on childhood cancer in early trial
NCT ID NCT00085930
First seen Jan 07, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This early-phase study tested a new approach for children with high-risk neuroblastoma, a cancer that often returns. Researchers took the patients' own immune cells (T cells) and modified them to better recognize and attack the cancer, while also training them to last longer in the body. The main goal was to check safety and see how long the cells survive. 19 children participated, and the treatment is still experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.